Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Reasons for treatment with Zarzio®: clinician assessment and Zarzio® treatment in patients given primary vs secondary/curative prophylaxis (analysis population, N = 1174)

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

  Breast (n = 356) Lung (n = 280) GI: colorectal (n = 103) GI: non-colorectal (n = 72) GYN: ovarian (n = 72) GYN: non-ovarian (n = 39) Head & neck (n = 105) Prostate (n = 66) Other (n = 81) Total (N = 1174) Primary prophylaxis(n = 772) Secondary/curative prophylaxis (n = 402) p value§
FN risk category according to clinician, n (%)    
 ≥ 20% 133 (37.3) 92 (32.8) 24 (23.3) 24 (33.3) 27 (37.5) 14 (35.9) 49 (46.7) 29 (43.9) 43 (53.1) 435 (37.1) 321 (41.6) 114 (28.4) <0.0001
 10–20% with risk factors 174 (48.9) 162 (57.9) 60 (58.3) 39 (54.2) 43 (59.7) 23 (59.0) 45 (42.8) 32 (48.5) 34 (42.0) 612 (52.1) 389 (50.4) 223 (55.5)  
 < 10% 49 (13.8) 26 (9.3) 19 (18.4) 9 (12.5) 2 (2.8) 2 (5.1) 11 (10.5) 5 (7.6) 4 (4.9) 127 (10.8) 62 (8.0) 65 (16.2)  
Reason for G-CSF prescription, n (%)*    
 Elderly patient 65 (18.3) 66 (23.6) 34 (33.0) 18 (25.0) 27 (37.5) 12 (30.8) 19 (18.1) 27 (40.9) 19 (23.5) 287 (24.4) 203 (26.3) 84 (20.9) 0.04
 Poor functional or nutritional status 35 (9.8) 78 (27.9) 17 (16.5) 21 (29.2) 15 (20.8) 4 (10.3) 45 (42.9) 13 (19.7) 21 (25.9) 249 (21.2) 184 (23.8) 65 (16.2) <0.01
 Low leucocyte levels 45 (12.6) 45 (16.1) 52 (50.5) 25 (34.7) 18 (25.0) 4 (10.3) 15 (14.3) 12 (18.2) 10 (12.3) 226 (19.3) 45 (12.6) 181 (45.0) <0.0001
 Concomitant pathologies 26 (7.3) 99 (35.4) 15 (14.6) 14 (19.4) 9 (12.5) 6 (15.4) 20 (19.0) 12 (18.2) 21 (25.9) 222 (18.9) 178 (23.1) 44 (10.9) <0.0001
 Low haemoglobin levels 3 (0.8) 22 (7.9) 7 (6.8) 10 (13.9) 10 (13.9) 2 (5.1) 2 (1.9) 12 (18.2) 8 (9.9) 76 (6.5) 38 (4.9) 38 (9.5) <0.01
 Prior FN 19 (5.3) 13 (4.6) 3 (2.9) 4 (5.6) 9 (12.5) 0 (0) 2 (1.9) 1 (1.5) 4 (4.9) 55 (4.7) 24 (3.1) 31 (7.7) <0.001
 FN in previous CT cycle 11 (3.1) 9 (3.2) 5 (4.9) 4 (5.6) 1 (1.4) 0 (0) 1 (1.0) 1 (1.5) 5 (6.2) 37 (3.2) 7 (0.9) 30 (7.5) <0.0001
 Prophylactic antibiotic 0 (0) 5 (1.8) 1 (1.0) 1 (1.4) 0 (0) 0 (0) 1 (1.0) 1 (1.5) 0 (0) 9 (0.8) 4 (0.5) 5 (1.2) 0.29ǁ
 Other reason** 219 (61.5) 106 (37.9) 31 (30.1) 23 (31.9) 31 (43.1) 20 (51.3) 40 (38.1) 33 (50.0) 37 (45.7) 540 (46.0) 391 (50.6) 149 (37.1) <0.0001
  1. *Multiple reasons could be given
  2. Primary prophylaxis for FN defined as G-CSF prophylaxis introduced during the first cycle of the current CT regimen.
  3. Other ST cohorts include urological outside prostate, sarcoma, thymic carcinoma, skin, bone, unknown primary, multiple independent sites.
  4. §Univariate statistical test
  5. ǁFisher test
  6. **Other reasons for G-CSF prescription include previous CT treatment, toxicity to CT, maintaining dose intensity, neutropenia, heavily pre-treated patients and prophylaxis
  7. CT chemotherapy, FN febrile neutropenia, G-CSF granulocyte colony-stimulating factor, GI gastrointestinal, GYN gynaecological